… therapy for ovarian cancer and its … ovarian cancer. The inherent hope with targeted therapies,
such as bevacizumab, is to achieve an antitumour response, while largely sparing damage …

The covid-19 pandemic has impacted the management of non-covid-19 illnesses. Epithelial
ovarian cancer (EOC) requires long-duration multidisciplinary treatment. Teleconsultation …

… These included six cases of endometrial cancer, 5 cases of ovarian cancer and 4 cases
of breast cancer that were treated by hormonal therapy or chemotherapy. Four conization …

… miR-27b binds to the 3′-untranslated region (3′-UTR) of VE-cadherin mRNA and
inhibits ovarian cancer cell-mediated VM through suppression of VE-cadherin expression [320]. …

… Melphalan has been used in ovarian cancer and is associated with a marked increase in the
risk of … in 32251 women treated for ovarian cancer. 109 In breast cancer patients, melphalan …

… ovarian cancer being the most lethal. One of the hallmark characteristics of ovarian cancer is
… therapies, from drug efflux proteins to ovarian cancer stem cells. The review also addresses …

… PIT compensates for this potential for collateral damage through antibody-mediated tumor-specific
accumulation of PSs and spatiotemporal control of light irradiation and PS activation. …

… cancers, with >30% reduction in survival at 6 months and >17% reduction in survival at 3
months for patients with stage 2 or 3 cancers of the bladder, lung, oesophagus, ovary, liver, …

… eradication of disseminated cancers. Ovarian cancer is the fifth leading cause of cancer death
in … Although the collateral damage inflicted on the dividing bone marrow progenitors, gut …

… As part of their infection cycle, many bacteria secrete toxins that cause DNA damage in host
cells. Genomic instability is a hallmark of cancer development because DNA damage may …